

1. Anand P, Kunnumakkara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. *Pharm Res* 2008;25:2097–2116.
2. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? *Curr Opin Pharmacol* 2009;9:351–369.
3. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? *Science* 2013;339:286–291.
4. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. *Front Biosci* 2008;13:5094–5107.
5. Karin M. Nuclear factor-kappaB in cancer development and progression. *Nature* 2006;441:431–436.
6. Aggarwal BB. Nuclear factor-kappaB: the enemy within. *Cancer Cell* 2004;6:203–208.
7. Chaturvedi MM, Sung B, Yadav VR, et al. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. *Oncogene* 2011;30:1615–1630.
8. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* 2003;3:745–756.
9. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood* 2012;119:651–665.
10. Iannitti T, Capone S, Gatti A, et al. Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy. *Int J Nanomed* 2010;5:955–960.
11. Zhao Y, Xu Y, Li Y, et al. NF-kappaB-mediated inflammation leading to EMT via miR-200c is involved in cell transformation induced by cigarette smoke extract. *Toxicol Sci* 2013;135:265–276.
12. Xu Y, Zhao Y, Xu W, et al. Involvement of HIF-2alpha-mediated inflammation in arsenite-induced transformation of human bronchial epithelial cells. *Toxicol Appl Pharmacol* 2013;272:542–550.
13. Liu K, Jiang M, Lu Y, et al. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. *Cell Stem Cell* 2013;12:304–315.
14. Yoon BN, Chon KM, Hong SL, et al. Inflammation and apoptosis in malignant transformation of sinonasal inverted papilloma: the role of the bridge molecules, cyclooxygenase-2, and nuclear factor kappaB. *Am J Otolaryngol* 2013;34:22–30.
15. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. *Methods Mol Biol* 2009;511:159–184.
16. Coste I, Le Corf K, Kfoury A, et al. Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. *J Clin Invest* 2010;120:3663–3667.
17. Parthasarathy S, Dhayaparan D, Jayanthi V, et al. Aberrant expression of epidermal growth factor receptor and its interaction with protein kinase C delta in inflammation associated neoplastic transformation of human esophageal epithelium in high risk populations. *J Gastroenterol Hepatol* 2011;26:382–390.
18. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. *Cell* 2009;139:693–706.
19. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis* 2009;30:1073–1081.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–674.
21. Canna K, McMillan DC, McKee RF, et al. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. *Br J Cancer* 2004;90:1707–1709.
22. Hilmy M, Bartlett JM, Underwood MA, et al. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. *Br J Cancer* 2005;92:625–627.
23. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br J Cancer* 2003;89:1028–1030.
24. Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. *Cancer* 2007;109:205–212.
25. Crumley AB, Stuart RC, McKernan M, et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. *J Gastroenterol Hepatol* 2008;23:e325–329.
26. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. *Oncology* 2007;73:215–220.
27. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. *Eur J Surg Oncol* 2008;34:55–60.
28. Huang ZL, Luo J, Chen MS, et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. *J Vasc Interv Radiol* 2011;22:702–709.
29. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol* 2009;27:5794–5799.
30. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. *Am J Surg* 2009;197:466–472.
31. Fox P, Hudson M, Brown C, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. *Br J Cancer* 2013;109:147–153.
32. Iwasaki Y, Ishizuka M, Kato M, et al. Usefulness of an inflammation-based prognostic score (mGPS) for predicting survival in patients with unresectable malignant biliary obstruction. *World J Surg* 2013;37:2222–2228.
33. Shafique K, Proctor MJ, McMillan DC, et al. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. *Prostate Cancer Prostatic Dis* 2012;15:195–201.
34. Kunisaki C, Takahashi M, Ono HA, et al. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. *Oncology* 2012;83:183–191.
35. Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. *Transl Res* 2012;160:146–152.
36. Burt BM, Bader A, Winter D, et al. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. *Clin Cancer Res* 2012;18:1568–1577.
37. Sethi G, Shammugam MK, Ramachandran L, et al. Multifaceted link between cancer and inflammation. *Biosci Rep* 2012;32:1–15.
38. Papi A, Guarnieri T, Storci G, et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. *Cell Death Differ* 2012;19:1208–1219.
39. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. *J Clin Oncol* 2009;27:3437–3444.
40. Deans DA, Wigmour SJ, Gilmour H, et al. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. *Br J Cancer* 2006;95:1568–1575.
41. Chen LS, Balakrishnan K, Gandhi V. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. *Biochem Pharmacol* 2010;80:1936–1945.
42. Sharma-Walia N, Paul AG, Bottero V, et al. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. *PLoS Pathog* 2010;6:e1000777.
43. Modiano JF, Belgrau D, Cutter GR, et al. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. *Mol Ther* 2012;20:2234–2243.
44. Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. *Cancer Immunol Immunother* 2011;60:1721–1728.
45. Hu B, Elinav E, Flavell RA. Inflammation-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. *Cell Cycle* 2011;10:1936–1939.
46. Sugar LM. Inflammation and prostate cancer. *Can J Urol* 2006;13(Suppl 1):46–47.
47. Safate-Ribeiro AV, Ribeiro U, Jr., Clarke MR, et al. Relationship between persistence of *Helicobacter pylori* and dysplasia, intestinal metaplasia, atrophy, inflammation, and cell proliferation following partial gastrectomy. *Dig Dis Sci* 1999;44:243–252.
48. Ihrig M, Schrenzel MD, Fox JG. Differential susceptibility to hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with *Helicobacter hepaticus*. *Am J Pathol* 1999;155:571–582.
49. de Paula AM, Carvalhais JN, Domingues MG, et al. Cell proliferation markers in the odontogenic keratocyst: effect of inflammation. *J Oral Pathol Med* 2000;29:477–482.
50. Kaplan I, Hirshberg A. The correlation between epithelial cell proliferation and inflammation in odontogenic keratocyst. *Oral Oncol* 2004;40:985–991.
51. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bel-2, and cell proliferation in the glandular epithelium. *Prostate* 2004;61:60–72.
52. Demarzo MM, Martins LV, Fernandes CR, et al. Exercise reduces inflammation and cell proliferation in rat colon carcinogenesis. *Med Sci Sports Exerc* 2008;40:618–621.
53. Madson JC, Lynch DT, Tinkum KL, et al. Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation. *Am J Pathol* 2006;169:1402–1414.
54. Bondong S, Kiefel H, Hielscher T, et al. Prognostic significance of LICAM in ovarian cancer and its role in constitutive NF-kappaB activation. *Ann Oncol* 2012;23:1795–1802.
55. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. *Cell Cycle* 2009;8:3267–3273.
56. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. *Clin Cancer Res* 2009;15:425–430.
57. Kinoshita A, Onoda H, Imai N, et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. *BMC Cancer* 2013;13:52.

58. Toiyama Y, Miki C, Inoue Y, et al. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. *Exp Ther Med* 2011;2:95–101.
59. Kobayashi T, Teruya M, Kishiki T, et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. *Surgery* 2008;144:729–735.
60. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. *J Clin Oncol* 2000;18:1135–1149.
61. Clark ES, Weaver AM. A new role for cactinin in invadopodia: regulation of protease secretion. *Eur J Cell Biol* 2008;87:581–590.
62. Dai CX, Gao Q, Qiu SJ, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. *BMC Cancer* 2009;9:418.
63. Victor BC, Anbalagan A, Mohamed MM, et al. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. *Breast Cancer Res* 2011;13:R115.
64. van Golen KL, Bao LW, Pan Q, et al. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. *Clin Exp Metastasis* 2002;19:301–311.
65. Lehman HL, Van Laere SJ, van Golen CM, et al. Regulation of inflammatory breast cancer cell invasion through Akt1/PKBalph phosphorylation of RhoC GTPase. *Mol Cancer Res* 2012;10:1306–1318.
66. Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* 2007;130:440–455.
67. Offeren BV, Knap MM, Marcussen N, et al. Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis. *Br J Cancer* 2002;87:1422–1430.
68. Rajashekhar G, Willuweit A, Patterson CE, et al. Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation. *J Vasc Res* 2006;43:193–204.
69. Voronov E, Carmi Y, Apte RN. Role of IL-1-mediated inflammation in tumor angiogenesis. *Adv Exp Med Biol* 2007;601:265–270.
70. Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. *Int J Inflamm* 2011;2011:908468.
71. Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherosclerosis and angiogenesis. *Thromb Haemostasis* 2013;109:391–398.
72. Benest AV, Kruse K, Savant S, et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. *PLoS One* 2013;8: e70459.
73. Lu SL, Reh D, Li AG, et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. *Cancer Res* 2004;64:4405–4410.
74. Berger AC, Tang G, Alexander HR, et al. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. *J Immunother* 2000;23:519–527.
75. Klein S, de Fougerolles AR, Blaikie P, et al. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. *Mol Cell Biol* 2002;22:5912–5922.
76. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. *Cancer Sci* 2008;99:1501–1506.
77. Ye YN, Liu ES, Shin VY, et al. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. *Toxicology* 2004;203:179–188.
78. Czabanka M, Korherr C, Brinkmann U, et al. Influence of TBK-1 on tumor angiogenesis and microvascular inflammation. *Front Biosci* 2008;13:7243–7249.
79. Solinas G, Marchesi F, Garlanda C, et al. Inflammation-mediated promotion of invasion and metastasis. *Cancer Metastasis Rev* 2010;29:243–248.
80. Affara NI, Coussens LM. IKKalpha at the crossroads of inflammation and metastasis. *Cell* 2007;129:25–26.
81. Kayser K, Bulzebruck H, Ebert W, et al. Local tumor inflammation, lymph node metastasis, and survival of operated bronchus carcinoma patients. *J Natl Cancer Inst* 1986;77:77–81.
82. Hobson J, Gummadidala P, Silverstrim B, et al. Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis. *Breast Cancer Res Treat* 2013;139:391–401.
83. Robinson-Smith TM, Isaacsohn I, Mercer CA, et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. *Cancer Res* 2007;67:5708–5716.
84. Khatib AM, Auguste P, Fallavollita L, et al. Characterization of the host pro-inflammatory response to tumor cells during the initial stages of liver metastasis. *Am J Pathol* 2005;167:749–759.
85. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. *Glycoconj J* 1997;14:585–591.
86. Geng JG, Chen M, Chou KC. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. *Curr Med Chem* 2004;11:2153–2160.
87. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell* 2006;124:263–266.
88. Siegel G, Malmsten M. The role of the endothelium in inflammation and tumor metastasis. *Int J Microcirc Clin Exp* 1997;17:257–272.
89. Wang W, Xu GL, Jia WD, et al. Ligand of TLR2 by versican: a link between inflammation and metastasis. *Arch Med Res* 2009;40:321–323.
90. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. *Nature* 2007;446:690–694.
91. Kim MP, Park SI, Kopetz S, et al. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. *Cell Tissue Res* 2009;335:249–259.
92. Melnikova V, Bar-Eli M. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. *Cancer Metastasis Rev* 2007;26:359–371.
93. Jing Y, Han Z, Liu Y, et al. Mesenchymal stem cells in inflammation micro-environment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. *PLoS One* 2012;7:e3272.
94. Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007;128:683–692.
95. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. *Annu Rev Pharmacol Toxicol* 2005;45:629–656.
96. Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique players in shaping the epigenetic histone code. *Ann N Y Acad Sci* 2003;983:84–100.
97. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. *Nature* 1993;366:362–365.
98. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. *Proc Natl Acad Sci U S A* 1993;90:11995–11999.
99. Yara S, Lavoie JC, Beaulieu JF, et al. Iron-ascorbate-mediated lipid peroxidation causes epigenetic changes in the antioxidant defense in intestinal epithelial cells: impact on inflammation. *PLoS One* 2013;8:e63456.
100. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001;345:784–789.
101. Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. *Clin Cancer Res* 2006;12:989–995.
102. Nakajima T, Maekita T, Oda I, et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. *Cancer Epidemiol Biomarkers Prev* 2006;15:2317–2321.
103. Perri F, Cotugno R, Piepoli A, et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. *Am J Gastroenterol* 2007;102:1361–1371.
104. Achyut BR, Bader DA, Robles AI, et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. *PLoS Genet* 2013;9:e1003251.
105. Blanco D, Vicent S, Fraga MF, et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. *Neoplasia* 2007;9:840–852.
106. Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. *Mol Cell* 2010;39:493–506.
107. Suzuki H, Toyota M, Kondo Y, et al. Inflammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome. *Methods Mol Biol* 2009;512:55–69.
108. Valinluck V, Sowers LC. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. *Cancer Res* 2007;67:5583–5586.
109. Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. *Eur Respir J* 1997;10:2411–2418.
110. Li QB, Sun XJ, Xu YZ, et al. Use of Fourier-transform infrared spectroscopy to rapidly diagnose gastric endoscopic biopsies. *World J Gastroenterol* 2005;11:3842–3845.
111. Difucua B, Keith I, Teunissen B, et al. Diagnosis of prostatic inflammation: efficacy of needle biopsies versus tissue blocks. *Urology* 2005;65:445–448.
112. Vendrame E, Martinez-Maza O. Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. *J Proteome Res* 2011;10:113–119.
113. Baicus C, Caraiola S, Rimbas M, et al. Utility of routine hematological and inflammation parameters for the diagnosis of cancer in involuntary weight loss. *J Investig Med* 2011;59:951–955.
114. DePew ZS, Gonsalves WI, Roden AC, et al. Granulomatous inflammation detected by endobronchial ultrasound-guided transbronchial needle aspiration in patients with a concurrent diagnosis of cancer: a clinical conundrum. *J Bronchology Interv Pulmonol* 2012;19:176–181.
115. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. *BMC Cancer* 2013;13:158.
116. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. *Science* 2013;339:1546–1558.
117. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. *Lancet Oncol* 2013;14:e218–228.
118. Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. *Sci Transl Med* 2012;4(127):127rv4.